


Claims.

1. A tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula I



Formula I

5

Wherein

X is CH₂, O or S;R represents 1-3 substituents independently selected from H, (C₁₋₄)alkyl, (C₁₋₄)-alkyloxy and halogen;10 R₁ is (C₅₋₈)cycloalkyl;R₂ is H or (C₁₋₄)alkyl;R₃, R_{3'}, R₄, R_{4'}, R₅, R_{5'} and R₆' are independently hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, OH or halogen;15 R₆ is hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, OH or halogen; orR₆ forms together with R₇ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S;R₇ forms together with R₆ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; or20 R₇ is H, (C₁₋₄)alkyl or (C₃₋₅)cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C₁₋₄)alkyloxy; or a pharmaceutically acceptable salt thereof.25 2. The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R is H and R₁ is cyclopentyl or cyclohexyl.3. The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1 or 2, wherein X is CH₂ or O.30 4. The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of any one of claims 1-3, wherein R, R₂, R₃, R_{3'}, R₄', R₅, R_{5'} and R₆' are H; R₄, R₆ and R₇ are independently

H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl

5. The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of any one of claims 1-4

for use in therapy.

6. A pharmaceutical composition comprising a tricyclic 1-[(indol-3-yl)carbonyl]-piperazine derivative of any one of claims 1-4 together with a pharmaceutically acceptable carrier therefor.

10

7. Use of a tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of Formula I as defined in claim 1, in the preparation of a medicament for the treatment of pain.

15